Amdocs (DOX) Backlog And AI Push Put Valuation Back In Focus

Simply Wall St

Amdocs (DOX) has drawn fresh attention after reporting a 12 month backlog of about $4.28b, supported by new customer agreements for its agentic operating system and the completion of the Matrixx Software acquisition.

See our latest analysis for Amdocs.

Despite recent contract wins and the Matrixx Software acquisition, Amdocs’ share price return has been mixed. The stock recorded a 7-day gain of 6.95% and a 30-day rise of 8.87%, set against a year-to-date decline of 30.49% and a 1-year total shareholder return decline of 31.84%. This suggests improving short-term momentum following a weaker multi-year period.

If you are looking beyond Amdocs’ recent AI-focused wins, this is a good moment to see what else is moving and uncover 55 AI infrastructure stocks

Amdocs now trades at a steep discount to both analyst targets and some intrinsic value estimates, even after the recent rebound. Is this simply the market mispricing AI and backlog potential, or is it a clear warning about risk that deserves respect?

Most Popular Narrative: 32.1% Undervalued

Amdocs last closed at $55.72, while the most followed narrative assigns a fair value of $82.03. That sets up a wide gap for investors to assess.

At the heart of its operations, Amdocs serves as a critical bridge between legacy infrastructure and modern digital requirements, supporting complex telco IT environments with a focus on business support systems (BSS) and operations support systems (OSS). With a deep, long-standing domain expertise that the company describes as its "native language," Amdocs is currently evolving from its traditional service-provider roots into a GenAI-native transformation specialist.

Read the complete narrative. Read the complete narrative.

According to HarishPK, this fair value leans heavily on recurring revenue, high renewal rates and detailed cash flow modelling. Want to see which cash flow assumptions, growth ranges and margin paths are doing the heavy lifting in that $82.03 figure, and how those inputs stack up against the current $55.72 share price?

Result: Fair Value of $82.03 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to weigh risks such as slower telecom IT spending or potential Amdocs execution missteps on large GenAI and cloud projects that underpin the thesis.

Find out about the key risks to this Amdocs narrative.

Next Steps

If the mixed signals around Amdocs leave you unsure, this is a good time to review the numbers yourself and move quickly to form your own stance. To see what optimism is building into the thesis, start with the 5 key rewards.

Looking for more investment ideas beyond Amdocs?

If Amdocs has your attention, do not stop there. Broaden your watchlist now so you are not relying on a single story for future decisions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Amdocs might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com